Cipla on Monday announced its partnership with Boehringer Ingelheim to co-market three oral anti-diabetic drugs namely, Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin).
Empagliflozin is approved for controlling glucose in patients with type-2 diabetes. It is also approved for minimising the risk of cardiovascular deaths in patients with type-2 diabetes as well as for established cardiovascular disease.
Empagliflozin+Linagliptin combination Tiptengio has a strong effect on lowering blood sugar levels along with curing multiple defects in type-2 diabetes. It is the world’s first approved combination of two inhibitors, which will reduce the number of pills for the patients and improve adherence to the prescribed treatment.
Meanwhile, Empagliflozin+Metformin combination Oboravo Met is for the newly-diagnosed patients of type-2 diabetes, who have higher baseline HbA1c levels.
With diabetes being the focus area of Cipla, the strategic partnership with Boehringer Ingelheim would aide it to reach the forefront of providing holistic diabetes care.
Cipla was trading at Rs 644.65 with a growth of 1.57 per cent at around 3.14 pm. Its 52-week high is Rs 696 while, 52-week low of Rs 356.75 on BSE.